Completed
Efficacy and Safety of Oral Famciclovir in Patients With Active Recurrent Genital Herpes
Led by Novartis · Updated on 2013-08-15
1461
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a phase III, multicenter, randomized, double-blind, parallel-group study to compare the efficacy and safety of a two-day treatment with famciclovir (500 mg loading dose followed by 250 mg 12-hourly) to standard five-day treatment with famciclovir (125 mg 12-hourly) in patients with active recurrent genital herpes. This study is not recruiting patients in the United States.
CONDITIONS
Brief Title
Efficacy and Safety of Oral Famciclovir in Patients With Active Recurrent Genital Herpes
Who Can Participate
Eligibility Criteria
Inclusion Criteria:
- Diagnosis of genital herpes
- Had at least 2 recurrences in past 12 months or 1 recurrence in past 6 months
Exclusion Criteria:
- - Currently taking suppressive herpes antiviral therapy
- Females who are pregnant, breast feeding or planning to become pregnant during study
- History of allergy to famciclovir or similar products (e.g. aciclovir, valaciclovir)
Other protocol-defined exclusion criteria may apply.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here